pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,659 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT825Endpoints630BioPharma Dive241onclive165Fierce Biotech92BioSpace91raps37globenewswire health
therapy area
allOncology4898Rare Disease763Hematology744Immunology688Cardiology673Pulmonology531Psychiatry & CNS
  • Vertex makes $10B deal for commercial endocrinology biotech Crinetics
    Vertex Pharmaceuticals is making the largest acquisition in its history, beefing up its commercial portfolio with a $10 billion takeover of Crinetics Pharmaceuticals. The Monday afternoon deal for…
    Endpoints · 24d ago↗ source
  • Obamacare rolls shrank dramatically in many states over the past year, new federal data shows
    States across the country saw steep drops in the number of people covered by the Affordable Care Act over the past year, according to new federal data.
    STAT · 24d ago↗ source
  • CMS proposes 340B cuts
    A proposed rule would cut the rates by which Medicare pays hospitals for 340B drugs by more than a third, reviving a similar policy introduced by the first Trump administration. CMS said on Thursda…
← prev
page 19 of 67
next →
28
fda medwatch21
fda press21
fda recalls18
503
Vaccines463
Endocrinology & Metabolism280
Ophthalmology248
Nephrology223
Pain221
Endpoints · 24d ago
↗ source
  • Fayus Inc., dba Yusol International Foods Recalls OLA-OLA POUNDED YAM Due to Undeclared Milk Allergen
    Fayus Inc., doing business as Yusol International Foods (Sacramento, CA) is voluntarily recalling OLA-OLA POUNDED YAM because the product may contain undeclared milk in the form of sodium caseinate…
    fda recalls · 24d ago↗ source
  • FDA approves 23 new drugs in first half, overcoming staff-cut concerns
    There's an answer emerging on the multibillion-dollar question of whether the Trump administration's gutting of FDA staff in April 2025 would slow down drug approvals: So far, so good. In the
    Endpoints · 24d ago↗ source
  • New CDER appointment elevates longtime GLP-1 reviewer
    Acting FDA CDER director Michael Davis has promoted a longtime FDA staffer as an acting deputy director at the drug center. Lisa Yanoff, an agency veteran with expertise in metabolic drug reviews,…
    Endpoints · 24d ago↗ source
  • STAT+: Online GLP-1 prescriptions are often fast, easy — and low on clinical oversight
    A new secret-shopper study found that GLP-1 prescriptions from telehealth sites aren't often backed by appropriate clinical care.
    STAT · 24d ago↗ source
  • Bristol Myers details Krazati confirmatory study failure in colorectal cancer
    While Americans geared up for the July 4 holiday, Bristol Myers Squibb laid out how a confirmatory trial for its drug Krazati failed in colorectal cancer. Patients taking Krazati plus another drug,…
    Endpoints · 24d ago↗ source
  • Roche aims to bolster breast cancer pipeline with early-stage Astex deal
    Monday’s deal between Otsuka’s subsidiary Astex Pharmaceuticals and Roche’s subsidiary Genentech is of interest not because it is big money — the upfront fee is just $25 million — but because of wh…
    Endpoints · 24d ago↗ source
  • Apogee details path to $10.9B AbbVie deal; UK starts drug pricing pilot
    Plus news about Brii Biosciences. 💰 How AbbVie got Apogee: The Chicago-area drug giant snagged Apogee Therapeutics for $10.9 billion last month after years of talking with the biotech. AbbVie held…
    Endpoints · 24d ago↗ source
  • STAT+: Four major biotech updates to catch up on
    Anthropic CEO talks drug discovery, Medicare proposes steep 340B drug payment cuts, and more biotech news
    STAT · 24d ago↗ source
  • Salk Institute’s president on NIH cuts, ‘all in’ on AI, and the Year of the Brain
    SAN DIEGO — From the president’s office at the Salk Institute, Gerald Joyce has a quintessential California view of hang gliders soaring over the Pacific Ocean. It’s been a little more turbulent fo…
    Endpoints · 24d ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Novartis acquisition, Republicans backing clinical trial diversity, and more
    Novartis is pushing deeper into antibody-drug conjugate development, paying $1.1 billion upfront to buy Myricx Bio
    STAT · 24d ago↗ source
  • The race for an Ebola therapy begins
    Male marathoners "hit the wall," mental health in 2026, and more Morning Rounds news
    STAT · 24d ago↗ source
  • Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform
    Novartis said Monday it will be spending $1.1 billion upfront to buy Myricx Bio, which has an antibody-drug conjugate payload platform that could offer an edge over current approaches. The Swiss dr…
    Endpoints · 24d ago↗ source
  • Opinion: The smart way to regulate the peptide boom
    “The FDA should pursue a structured, clinician-guided framework” on popular peptides, writes former surgeon general Jerome Adams.
    STAT · 24d ago↗ source
  • Opinion: Stopping doctors from ordering unnecessary diagnostic tests requires a structural fix
    “The medical industry has spent enormous effort making more advanced tests but expended little effort learning how to use tests correctly,” writes Daniel Morgan.
    STAT · 24d ago↗ source
  • STAT+: GOP lawmakers push Trump’s FDA to make sure clinical trials are diverse
    Supporters say clinical trial diversity is about making sure drugs and devices work, not about DEI.
    STAT · 24d ago↗ source
  • STAT+: I spoke to Anthropic’s CEO about how AI may affect biotech. Here’s what I learned
    Call AI in biotech hype at your peril. There are real reasons that pharmaceutical companies are embracing this technology right now.
    STAT · 24d ago↗ source
  • What does content creation do to mental health?
    This year at Vidcon, I was struck by how much of the conference’s programming was dedicated to the mental health of content creators.
    STAT · 24d ago↗ source
  • Anthropic launches Claude Science; House China panel probes trial sites; and more
    Happy Fourth of July! We’ve got a handful of stories worth checking out before the backyard barbecue begins. But first: a reminder to submit your nominations for this year’s Women in Biopharma ...
    Endpoints · 26d ago↗ source
  • Frutas y Hortalizas del Sur S.A. Initiates Recall of Frozen GreenWise Organic IQF Blueberries Due to Potential E. coli O145 Contamination
    July 3, 2026 – Frutas y Hortalizas del Sur S.A., San Carlos, Chile is recalling frozen GreenWise Organic IQF Blueberries 10 oz. Because it may be contaminated with Escherichia coli O145:H28 (E. col…
    fda recalls · 27d ago↗ source
  • When clinical AI gets real
    We’re heading toward a future in which certain parts of medical care are delivered without any humans involved. Cadence, which raised a $100 million Series C last week, is betting that it can make…
    Endpoints · 28d ago↗ source
  • Voluntary Recall of Two Lots of PEDIGREE® Can High Protein Chopped Chicken & Duck Flavor Wet Dog Food Due to Potential Fraudulent Distribution of Product Which May Contain Foreign Material
    FRANKLIN, Tenn., (July 2, 2026): Mars Petcare US, Inc. is issuing a voluntary recall for two lots of PEDIGREE® Can High Protein Chopped Chicken & Duck Flavor 13.2oz for dogs.
    fda recalls · 28d ago↗ source
  • Scribe Therapeutics files for IPO in test of appetite for early-stage biotechs
    Scribe Therapeutics filed for a Nasdaq IPO late Thursday. The move marks a pivotal moment for the biotech and the gene editing field. The novel CRISPR enzyme developer was created nine ...
    Endpoints · 28d ago↗ source